0VQA Stock Chart & Stats
$32.58
-$2.07(-5.83%)
At close: 4:00 PM EDT
$32.58
-$2.07(-5.83%)
Day’s Range― - ―
52-Week Range$23.09 - $43.15
Previous CloseN/A
Volume9.13K
Average Volume (3M)10.38K
Market Cap
$3.44B
Enterprise Value$4.04K
Total Cash (Recent Filing)$501.66M
Total Debt (Recent Filing)$4.09M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Oct 28, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding116,652,940
10 Day Avg. Volume8,702
30 Day Avg. Volume10,380
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$90.08Price Target Upside176.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical ExecutionFully enrolled Phase III studies provide a substantial clinical foundation and move VK2735 closer to pivotal data and potential regulatory filing. Progress across two large trials supports development credibility and creates a clearer path toward future commercialization in obesity treatment.
Promising VK2735 EfficacyMeaningful weight-loss results for both injectable and oral formulations support the therapeutic potential of VK2735 and broaden possible patient-use options. The reported efficacy, alongside mostly mild-to-moderate tolerability, strengthens the pipeline’s commercial relevance if confirmed in Phase III.
Funding Runway And Low LeverageCash resources extending into 2028 give Viking time to advance major trials without immediate reliance on new financing. Minimal debt also reduces fixed repayment obligations, preserving strategic flexibility while the company works toward clinical and regulatory milestones.
Bears Say
Pre-revenue Operating ModelThe absence of meaningful commercial revenue leaves Viking dependent on capital markets, partnerships, or future product approval to fund operations. Until a candidate is commercialized, rising development costs cannot be supported by recurring customer sales, increasing execution sensitivity.
Accelerating Losses And Cash BurnRapidly increasing losses and cash outflows indicate that the clinical platform requires substantially more funding as programs advance. Even with current liquidity, continued burn can reduce financial flexibility and create future dilution or financing pressure before revenue begins.
Maintenance-study UncertaintyThe abbreviated titration and short maintenance period may make early gastrointestinal tolerability signals harder to interpret and limit comparison with longer studies. Uncertainty in dosing durability and tolerability could affect extension design, development decisions, and eventual product positioning.
Viking Therapeutics News
0VQA FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest share price was $23.09 and its highest was $43.15 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.44B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 40 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 29, 2026. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.233 by $0.133.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 116,652,940 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.233. Following the earnings report the stock price went down -4.401%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in GB:0VQA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.08 (176.50% Upside)
$90.08 (176.50% Upside)
Blogger Sentiment
Bullish
GB:0VQA Sentiment 85%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
0VQA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial clinical progress: fully enrolled large Phase III programs for subcutaneous VK2735, positive Phase II efficacy for both subcutaneous and oral formulations (notably up to 14.7% and 12.2% mean weight loss, respectively), initiation of an early-stage amylin/calcitonin program (VK3019), and organizational hires to support commercialization. These scientific and pipeline milestones are balanced against materially higher R&D spend, widening net losses and a meaningful cash decline (~28.9% year-to-date). Management reiterated cash runway into 2028 and expects cash burn to taper, while noting upcoming maintenance study data and oral Phase III initiation later in the year. Overall, clinical momentum and promising efficacy data are dominant positives, while financial burn and early-stage uncertainties are notable negatives.View all GB:0VQA earnings summaries0VQA Stock 12 Month Forecast
Average Price Target
$90.08
▲(176.50% Upside)
Technical Analysis
NewAmsterdam Pharma Company
―
Mineralys Therapeutics, Inc.
―
Structure Therapeutics, Inc. Sponsored ADR
―
Kailera Therapeutics, Inc.
―
Parabilis Medicines, Inc.
―